Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFE

Model scores of the 29,894 trials active now.

Model score 22% for any early termination, 4% for termination due to slow enrollment. Past trials like this one (phase and sponsor type, started 2008–2016) ended terminated 16% of the time (370 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2019-12-26. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: subjectrandomizationventricularleftplacebo
  Phrases that lowered it: to evaluateevaluate thelungdrugefficacy
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: 25% (raises risk) · Sponsor's track record
• Has a data monitoring committee: Yes (raises risk) · Design
• Design: parallel (raises risk) · Design
• Drug's FAERS reports marked serious: 64.8% (lowers risk) · Drug's FDA history
• Drug's FAERS reports with a death: 18.2% (lowers risk) · Drug's FDA history
• Blinding: quadruple (lowers risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Minimum age: 18 (raises risk) · Who can join
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Disease area, respiratory: Yes (raises risk) · Disease area
• Primary purpose: treatment (raises risk) · Design
• Phase: 2/3 (raises risk) · Design
• Drug's FAERS reports before start: 38604 (lowers risk) · Drug's FDA history
• Number of arms: 2 (raises risk) · Design
• Sponsor's past trials: 32 (lowers risk) · Sponsor's track record
• Drug's FAERS reports in the prior 12 months: 9460 (lowers risk) · Drug's FDA history
• Disease area, cardiovascular: Yes (raises risk) · Disease area
• Collaborators: 0 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Open-label, Clinical Study to Evaluate the Safety and Tolerability of TreT in Subjects With PAH Currently Using Tyvaso NCT03950739 · started 2019 · scored riskier than 49% of active trials completed
• Beraprost-314d Added-on to Tyvaso® (BEAT) NCT01908699 · started 2013 · scored riskier than 90% of active trials completed
• A Phase 3 Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Participants With Pulmonary Hypertension (PH) Due to Chronic Obstructive Pulmonary Disease (COPD) NCT03496623 · started 2018 · scored riskier than 34% of active trials terminated
• An Open Label Extension Study to Evaluate Inhaled Treprostinil in Adult PH With ILD Including CPFE NCT02633293 · started 2016 · scored riskier than 81% of active trials terminated
• Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction NCT03037580 · started 2017 · scored riskier than 85% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.